Etoposide as a single agent in the treatment of mycosis fungoides: A retrospective analysis

Purnak, Seda; Azar, José; Mark, Lawrence A.

doi:10.1111/dth.12586

Cited by 7 publications

(8 citation statements)

References 25 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…11 Indeed, a previous retrospective study suggested that the efficacy rate of etoposide monotherapy for the treatment of MF was 69% (95% CI: 42.0%-87.6%), and the median duration of response was 43 (5-60) weeks. 12 Interestingly, in the present case series of MF treated with etoposide-based therapy as post mogamulizumab monotherapy, the efficacy rate and median duration of response tended to be better than in a previous report. 12 Not only efficacy, but also safety profiles are important to evaluate the clinical use of mogamulizumab monotherapy.…”

Section: Discussioncontrasting

confidence: 71%

“…12 Interestingly, in the present case series of MF treated with etoposide-based therapy as post mogamulizumab monotherapy, the efficacy rate and median duration of response tended to be better than in a previous report. 12 Not only efficacy, but also safety profiles are important to evaluate the clinical use of mogamulizumab monotherapy. 5 As the previous phase III, randomized trial suggested, various SAEs occur, but at a lower rate in patients treated with mogamulizumab monotherapy.…”

Section: Discussioncontrasting

confidence: 71%

See 1 more Smart Citation

Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real‐world case series

Amagai

Kambayashi

Ohuchi

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

Since the efficacy of mogamulizumab has been confirmed by a phase III, randomized study, mogamulizumab is one of the promising first-line therapies for advanced cutaneous T cell lymphoma (CTCL), though its efficacy is not completely satisfactory. Therefore, several anti-lymphoma drugs such as etoposide were recently used to enhance the anti-tumor effects of mogamulizumab for the treatment of mycosis fungoides (MF). In this report, the anti-tumor effects of mogamulizumab and post mogamulizumab therapy were retrospectively evaluated in 11 cases of CTCL in real-world clinical practice. The best response rate (RR) was 45.5% (95% confidence interval [CI], 21.3%-72.0%) for the total cohort, 50.0% (95%CI, 21.5%-78.5%) for the MF cohort, and 33.3% (95%CI, 5.6%-79.8%) for the primary cutaneous peripheral T cell lymphoma not otherwise specified (PCPTCL-NOS) cohort. The objective response rate (ORR) at 1 month (ORR1) for the total cohort was 45.5% (95%CI, 21.3%-72.0%), and ORR at 4 months (ORR4) was 27.3% (95%CI, 9.2%-57.1%). The mean time to next treatment (TTNT) was 16.0 weeks (3-100 weeks) for all patients, 16.5 months (3-100 weeks) for the MF cohort, and 9.0 (7-16) weeks for the PCPTCL-NOS cohort. The efficacy rate of etoposide-based therapy was 71.4% (95%CI, 35.9%-98.0%) for all patients, 80% (95%CI, 35.9%-98.0%) in the MF cohort, and 50% (95%CI, 9.5%-90.5%) in the PCPTCL-NOS cohort. The median duration of response was 182 (45-323) weeks. The safety profile of mogamulizumab monotherapy in the present cohort was comparable to the previous phase III, randomized trial. The present study suggests that the efficacy and safety profiles of mogamulizumab monotherapy as second-line therapy and beyond in a real-world Japanese cohort were comparable to those in the previous phase III, randomized trial.

show abstract

Section: Discussioncontrasting

confidence: 71%

Section: Discussioncontrasting

confidence: 71%

Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real‐world case series

Amagai

Kambayashi

Ohuchi

et al. 2022

Dermatologic Therapy

View full text Add to dashboard Cite

show abstract

“…In Japan, oral etoposide (25–50 mg daily for 3 weeks followed by an interval of 1 week) alone or in combination with oral prednisolone (10–20 mg daily) has been used for advanced stage MF/SS refractory to previous therapy 75 . In a recent retrospective study including 13 patients, low‐dose oral etoposide (50 mg every other day ~100 mg daily) showed an ORR of 67% 76 …”

Section: Current Understanding Of Cutaneous Lymphomasmentioning

confidence: 99%

“…75 In a recent retrospective study including 13 patients, low-dose oral etoposide (50 mg every other day ~100 mg daily) showed an ORR of 67%. 76 Gemcitabine has been used for the treatment of a variety of malignant tumors including CTCL. In a phase II trial targeting stage IIB/III MF that had been refractory to previous treatments, gemcitabine showed an ORR of 70% with a CR rate of 10%.…”

Section: E52mentioning

confidence: 99%

Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020

Ohtsuka

Hamada

Miyagaki

et al. 2020

The Journal of Dermatology

View full text Add to dashboard Cite

Since the publication of the Japanese “Guidelines for the management of cutaneous lymphomas” in 2011, the World Health Organization (WHO) classification of hematolymphoid neoplasms and the WHO–European Organisation for Research and Treatment of Cancer classification for primary cutaneous lymphomas were updated and a number of novel systemic drugs for cutaneous T‐cell lymphoma had been approved in Japan. In 2020, we revised the Japanese guidelines for the management of cutaneous lymphomas with consideration of the recent advances in the understanding of the pathophysiology and classification of cutaneous lymphomas together with the update of treatment strategies reflecting the advent of novel drugs. In addition to a brief explanation of epidemiology, diagnosis, staging system, prognosis and management of each subtype of cutaneous lymphomas, the recommendations for nine clinical questions regarding treatment options that can vary even among experts are also described. A systematic review process and determination of recommendations in answer to each clinical question have been performed in accordance with the Grading of Recommendations, Assessment, Development and Evaluation scheme by a multidisciplinary expert panel consisting of dermatologists, a hematologist and a radiation oncologist. In this article, we present the outlines of the revised Japanese “Guidelines for the management of cutaneous lymphomas”.

show abstract

“…In a retrospective study of 13 patients with MF conducted in the USA, nine patients (69%) responded to low‐dose etoposide (50 mg every other day to 100 mg daily p.o., or 150 mg once a week i.v. ); median duration of response was 43 weeks 60 …”

Section: Current and Emerging Therapies For Cutaneous Lymphomamentioning

confidence: 99%

Current treatment strategies and emerging therapies for cutaneous lymphoma

Yonekura

2021

The Journal of Dermatology

View full text Add to dashboard Cite

Primary cutaneous lymphomas are defined as non-Hodgkin lymphomas presenting in the skin with no evidence of extracutaneous disease at the time of diagnosis. Primary cutaneous lymphoma includes a heterogeneous group of cutaneous T-cell lymphomas (CTCL) and cutaneous B-cell lymphomas (CBCL). 1 In Japan, 74.9% of primary cutaneous lymphomas are CTCL, which is much higher than the proportion of CBCL (21.1%). Among CTCL, mycosis fungoides (MF) accounts for the majority at 48.0%, followed by primary cutaneous CD30-positive lymphoproliferative disorders (9.4%), adult T-cell leukemia/lymphoma (ATL, 8.5%) and peripheral T-cell lymphoma, not otherwise specified (PTCL-NOS, 6.5%). 2 In recent years, many new therapeutic agents have been developed to treat cutaneous lymphomas, especially CTCL. Some of these agents were developed in Japan or approved in Japan prior to approval in Europe or the USA. Therefore, many therapeutic agents are currently available in Japan.This review summarizes the current treatment strategies for cutaneous lymphomas, especially CTCL, and emerging therapies for MF, Sézary syndrome (SS), primary cutaneous anaplastic large cell lymphoma (pcALCL), ATL, and CBCL. | CURRENT THER APEUTI C S TR ATEG IE S FOR CUTANEOUS LYMPHOMAPreviously, for early stage MF or SS, topical corticosteroids, ultraviolet (UV) irradiation, oral etretinate, or a combination thereof, was initially used. In resistant cases, interferon (IFN) was administered. Single-agent or combination chemotherapy was selected for advanced disease. Local radiotherapy (RT) was performed for local tumors. Over the last decade, several new agents have been introduced, which has expanded treatment options.Recently, topical therapy or UV irradiation, which are skindirected therapies (SDT), has been selected as initial treatment for early stage MF or SS. RT is a type of SDT that is used to treat treatment-resistant plaques and tumors. SDT is used in early stages and also in advanced stages in combination with systemic therapies.

show abstract

Etoposide as a single agent in the treatment of mycosis fungoides: A retrospective analysis

Cited by 7 publications

References 25 publications

Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real‐world case series

Cutaneous T cell lymphoma treated with mogamulizumab monotherapy and mogamulizumab plus etoposide combined therapy: A real‐world case series

Outlines of the Japanese guidelines for the management of primary cutaneous lymphomas 2020

Current treatment strategies and emerging therapies for cutaneous lymphoma

Contact Info

Product

Resources

About